MOREPEN LAB. LTD
MOREPENLAB · General/Diversified · NSE
₹49
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for MOREPENLAB yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
4/9
Economic Moat
None
Confidence
34%
ROE
7.6%
Debt/Equity
0.17
WACC
11.1%
Market Cap
₹2,705 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.9%
Return on capital employed
EV / EBITDA
24.2×
Enterprise multiple
Debt / EBITDA
2.1×
Leverage vs earnings
Interest Coverage
20.9×
EBIT covers interest
Current Ratio
2.32×
Short-term liquidity
Asset Turnover
1.00×
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
MOREPENLAB · last 9 annual periods
ROE
7.6%
ROCE
11.9%
Operating Margin
—
Debt / Equity
0.17×
PE
36.6×
EV / EBITDA
16.5×
Historical Financials
MOREPENLAB · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1542 Cr | ₹1414 Cr | ₹1682 Cr | ₹1812 Cr | ₹1806 Cr | +4.0% |
| EBITDA | ₹157 Cr | ₹85.7 Cr | ₹173 Cr | ₹192 Cr | ₹173 Cr | +2.5% |
| EBIT | ₹119 Cr | ₹57.7 Cr | ₹139 Cr | — | — | +3.9% |
| PAT | ₹102 Cr | ₹38.7 Cr | ₹96.2 Cr | ₹118 Cr | ₹94.9 Cr | -1.7% |
| EPS (diluted) | ₹1.96 | ₹0.77 | ₹1.88 | — | — | -1.0% |
| CFO | ₹-60.2 Cr | ₹-91.2 Cr | ₹73.4 Cr | ₹32.1 Cr | ₹32.6 Cr | — |
| CapEx | ₹-67.4 Cr | ₹-46.0 Cr | ₹-81.3 Cr | ₹-214 Cr | ₹-161 Cr | — |
| FCF | ₹-128 Cr | ₹-137 Cr | ₹-8.0 Cr | ₹-182 Cr | ₹-128 Cr | — |
| Total Assets | ₹1070 Cr | ₹1110 Cr | ₹1293 Cr | ₹1778 Cr | ₹1936 Cr | +16.0% |
| Total Debt | ₹18.6 Cr | ₹25.2 Cr | ₹29.0 Cr | ₹105 Cr | ₹208 Cr | +82.9% |
| Shareholders' Equity | ₹579 Cr | ₹753 Cr | ₹847 Cr | ₹1156 Cr | ₹1246 Cr | +21.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MOREPENLAB vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 HIKAL HIKAL | — | — | Pending | -4.1% | — |
SOLARA SOLARA | — | — | Pending | 0.0% | — |
 UNICHEMLAB UNICHEM LABORATORIES LTD | -14.7% | 37 | Near Fair Value | 9.8% | — |
 INDOCO INDOCO | — | — | Pending | -10.1% | — |
 IOLCP IOL CHEM AND PHARMA LTD | -24.5% | 54 | Near Fair Value | 7.9% | 15.5× |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹0.20/sh
Last payout
2025-08-29
₹0.20
Peak payout
₹0.20
Trailing yield
0.41%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of MOREPENLAB →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MOREPENLAB →
Compare
Head-to-head with peers
Compare MOREPENLAB side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MOREPENLABNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.